Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 3/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 3/20 | 0.55 |
| ▸ | CDC25B | P30305 | 2/20 | 0.55 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | CDC25A | P30304 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL700595 | 0.90 | AKR1C3 (0.85) | AKR1C3GAAMAPTALDH1A1ATM | |
| SCHEMBL29447165 | 0.90 | AKR1C3 (0.85) | AKR1C3GAAMAPTALDH1A1ATM | |
| Fluoride SCHEMBL28319246 | 0.87 | AKR1C3 (0.81) | AKR1C3GAAMAPTALDH1A1ATM | |
| SCHEMBL28883310 | 0.87 | AKR1C3 (0.81) | AKR1C3GAAMAPTALDH1A1ATM | |
| SCHEMBL29163962 | 0.85 | AKR1C3 (0.77) | AKR1C3GAAMAPTALDH1A1ATM | |
| Ethylene SCHEMBL27279241 | 0.85 | AKR1C3 (0.77) | AKR1C3GAAMAPTALDH1A1ATM | |
| 2-Benzoylbenzoic Acid SCHEMBL27701515 | 0.84 | AKR1C3 (0.91) | AKR1C3GAAMAPTALDH1A1ATM | |
| Hydrogen Peroxide SCHEMBL17544681 | 0.84 | AKR1C3 (0.68) | AKR1C3GAAMAPTALDH1A1ATM | |
| 2-Benzoylbenzoic Acid SCHEMBL30296847 | 0.83 | AKR1C3 (1.00) | AKR1C3GAAMAPTALDH1A1ATM | |
| 2-Benzoylbenzoic Acid SCHEMBL76332 | 0.83 | AKR1C3 (1.00) | AKR1C3GAAMAPTALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810971-B1 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | claimed |
| EP-1606287-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | claimed |
| US-8383810-B2 | Process for the synthesis of azetidinones | MERCK SHARP & DOHME CORP. (US) | 2013-02-26 | — | — | US | claimed |
| EP-1831162-B1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120083601-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING-PLOUGH CORPORATION (US) | 2012-04-05 | — | — | US | claimed |
| US-20110144327-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2011-06-16 | — | — | US | claimed |
| US-7741289-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-22 | — | — | US | claimed |
| US-7732413-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| EP-1601669-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORP (US) | 2008-12-24 | — | — | EP | claimed |
| US-7459442-B2 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION (US) | 2008-12-02 | — | — | US | claimed |
| US-20060135755-A1 | Process for the synthesis of azetidinones | SCHERING CORPORATION | 2006-06-22 | — | — | US | claimed |
| EP-1606287-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2005-12-21 | — | — | EP | claimed |
| EP-1601668-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1601669-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2005-12-07 | — | — | EP | claimed |
| US-20040198700-A1 | Administering to a patient an azetidinone compound containing at least 3 phenyl rings fo rprevention of a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer's disease | SCHERING CORPORATION | 2004-10-07 | — | — | US | claimed |
| WO-2004081002-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| WO-2004081003-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLETEROLEMIA | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| WO-2004081004-A1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | SCHERING CORPORATION (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040180861-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION | 2004-09-16 | — | — | US | claimed |
| US-20040180860-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | SCHERING CORPORATION | 2004-09-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083601-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | LSS, ASNS, CYP51A1 | AKR1C3 1210/4885GAA 687/4885MAPT 3548/4885 |
| US-20110144327-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | LSS, ASNS, CYP51A1 | AKR1C3 1210/4885GAA 687/4885MAPT 3548/4885 |
| US-20040198700-A1 | Administering to a patient an azetidinone compound containing at least 3 phenyl rings fo rprevention of a vascular condition, diabetes, obesity, stroke, lowering a concentration of a sterol or stanol in plasma of a mammal, preventing demyelination or treating Alzheimer's disease | APOB, CYP46A1, NR1H3 | AKR1C3 144/4885GAA 1484/4885MAPT 840/4885 |
| US-20040180860-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | AKR1C3 342/4885GAA 1002/4885MAPT 3020/4885 |
| US-20040180861-A1 | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof | APOB, NPC1L1, CYP46A1 | AKR1C3 342/4885GAA 1002/4885MAPT 3020/4885 |
| US-20060135755-A1 | Process for the synthesis of azetidinones | LSS, ASNS, CYP51A1 | AKR1C3 1210/4885GAA 687/4885MAPT 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.